Laurus Labs
Drug Manufacturers - Specialty & Generic · LAURUSLABS
Large CapHealthcareHigh Growth
Dr. Satyanarayana Chava
Executive Director and CEO · Transformational
Company DNA
Innovation-Led
About
Laurus Labs is a Large Cap company in the Healthcare sector, listed on NSE as LAURUSLABS. With a market cap of ₹55K Cr and revenue of ₹6K Cr, it is currently in the High Growth phase. Known for its Innovation-Led culture and Fast-Follower approach to innovation, the company operates at a Startup-Speed pace. Driven by founder's R&D background, heavily investing in proprietary drug development and scientific problem-solving. Its strategic mandate: Needs to move up the value chain from APIs to advanced CDMO services and specialized biotech to sustain growth.
FAQ
What kind of company is Laurus Labs?
Laurus Labs is a Large Cap Healthcare company (LAURUSLABS) in the High Growth phase with a market cap of ₹55K Cr. It is classified as Innovation-Led in culture.
What is Laurus Labs's culture and work environment like?
Laurus Labs has a Innovation-Led culture with Fast-Follower innovation DNA and a Startup-Speed pace of execution. Employee brand: Learning Ground. Customer relationship style: B2B-Enterprise. Driven by founder's R&D background, heavily investing in proprietary drug development and scientific problem-solving.
Who leads Laurus Labs?
Laurus Labs is led by Dr. Satyanarayana Chava (Executive Director and CEO), a Transformational leader with 33 years of experience.
What are Laurus Labs's financials?
Laurus Labs reported revenue of ₹6K Cr in FY25 with a 5-year revenue CAGR of 4.1%. Operating margin: 11.4%. Market cap: ₹55K Cr.
Culture & Strategy
CultureInnovation-Led
InnovationFast-Follower
PaceStartup-Speed
PurposeMission-First
CustomerB2B-Enterprise
EmployeeLearning Ground
BrandTechnical-Expert
LifecycleHigh Growth
Driven by founder's R&D background, heavily investing in proprietary drug development and scientific problem-solving.
Mandate
Needs to move up the value chain from APIs to advanced CDMO services and specialized biotech to sustain growth.
Needs to move up the value chain from APIs to advanced CDMO services and specialized biotech to sustain growth.
Financials
Revenue FY25₹6K Cr
PAT FY25₹358 Cr
Rev CAGR 5Y4.1%
OPM11.4%
NPM6.5%
ROE8%
ROCE10.8%
P/E64.1
Fwd P/E53.8
P/B11.3
D/E44.8
Mkt Cap₹55K Cr
Promoter32.2%
Institutional43.2%
Similar Culture
Could You Lead Laurus Labs?
Take the Genome Benchmark →